A 71-year-old woman was admitted to hospital because of poor glycemic control and liver dysfunction. Although the patient's diabetes had been well-controlled with glibenclamide and pioglitazone, the pioglitazone had been discontinued because of an adverse effect on body weight gain and edema. The patient's HbA1C level subsequently rose from 7% to 11.6%. At admission, her BMI was 40.8 kg/m2 and she exhibited hypertension, hyperlipidemia, and microalbuminuria. A lacunar brain infarction was also diagnosed. The patient's fasting blood glucose level was 302 mg/dl, her serum IRI was 14.7 μU/ml, a hypoglycemic response was not obtained on an insulin tolerance test, and her fasting blood glucose was 219 mg/dl, and her postprandial blood glucose was 457 mg/dl at an insulin dosage of 1 U/kg body weight. Although she did not drink alcohol, she exhibited mild liver dysfunction: AST, 80 U/l; ALT, 70 U/l; γGTP, 102 U/l. A liver biopsy was performed, and the histological findings were compatible with a diagnosis of NASH. When 6 mg of glimepiride, a sulfonylurea with an insulin-sensitizing extrapancreatic effect, was added to the patient's insulin therapy, her blood glucose control improved markedly: fasting blood glucose, 76 mg/dl; postprandial blood glucose, 135 mg/dl; insulin dosage, 0.5 U/kg body weight. When insulin or oral hypoglycemic agents alone fail to control blood glucose in patients with type 2 diabetic associated with NASH, a combination therapy of glimepiride and insulin is recommended.
|Number of pages||7|
|Journal||Journal of the Japan Diabetes Society|
|Publication status||Published - 2003|
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism